Table 2.
Outcomes
| Outcomes | Overall (n = 91) | Linezolid (n = 40) | Vancomycin (n = 51) |
|---|---|---|---|
| Treatment failureA | 17 (18.7%) | 4 (10%) | 13 (25.5%) |
| Persistence of infection; n (%) | 9 (9.9%) | 1 (2.5%) | 8 (15.7%) |
| Relapse of infection; n (%) | 6 (6.6%) | 3 (7.5%) | 3 (5.9%) |
| Infection-related death; n (%) | 4 (4.4%) | 0 (0%) | 4 (7.8%) |
| Death; n (%) | 5 (5.5%) | 0 (0%) | 5 (9.8%) |
| Adverse events; n (%) | 10 (11%) | 1 (2.5%) | 9 (17.6%) |
A: Two patients experiment several outcomes of interest in vancomycin group: one patient had an infection persistence and after the end of antimicrobial treatment he had a relapse of his infection; and a second patient had infection relapse and died